A Phase 1 Open-label, Multicenter study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors.
- Haydon, Andrew (Primary Chief Investigator (PCI))
- Hawkins, Cheryl-Ann, (Project Manager)
Project: Research